---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007514"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-10-01T11:45:14+00:00"
generated_at: "2026-10-12T14:15:29.098591+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Valion Bio completes oral mucosal Entolimod formulation work with Shear Kershman Laboratories

## Summary
- Valion Bio and Shear Kershman Laboratories completed formulation work for an oral mucosal Entolimod using SKL's BioViscid drug-delivery platform.
- The program is a potential second, needle-free pathway alongside Valion's injectable Entolimod; next study will test measurable systemic exposure to Entolimod.
- Valion estimates U.S. doses for oral mucosal Entolimod could be 10 to 40 times its injectable program, assuming supply to ~2.0M military, 1.0M firefighters and 790,000 law enforcement officers.
- Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod for acute radiation syndrome and radiation-induced neutropenia.
- The release says all FDA-approved products address only hematopoietic ARS, and no treatment is approved for the gastrointestinal indication.

## SEC filing metadata
- accession: 0001683168-26-007514
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-10-01T11:45:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/0001683168-26-007514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007514
- JSON: https://secwatch.observer/filing/0001683168-26-007514.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.